VEGFA and ovarian carcinoma: It is unknown whether VEGF receptor antagonists would contribute to the development of PAH, but two patients developed PH were reported in patients who had ovarian cancer received bevacizumab (recombinant humanized monoclonal antibody against VEGF-A) (Garcia et al., 2008).